Bibliographies thématiques / Anti-CD20 monoclonal antibodie

Sommaire

Articles de revues
Thèses
Chapitres de livres
Actes de conférences

Littérature scientifique sur le sujet « Anti-CD20 monoclonal antibodie »

Auteur : Grafiati

Publié le 9 mars 2023

Créez une référence correcte selon les styles APA, MLA, Chicago, Harvard et plusieurs autres

Choisissez une source :

Consultez les listes thématiques d’articles de revues, de livres, de thèses, de rapports de conférences et d’autres sources académiques sur le sujet « Anti-CD20 monoclonal antibodie ».

À côté de chaque source dans la liste de références il y a un bouton « Ajouter à la bibliographie ». Cliquez sur ce bouton, et nous générerons automatiquement la référence bibliographique pour la source choisie selon votre style de citation préféré : APA, MLA, Harvard, Vancouver, Chicago, etc.

Vous pouvez aussi télécharger le texte intégral de la publication scolaire au format pdf et consulter son résumé en ligne lorsque ces informations sont inclues dans les métadonnées.

Articles de revues sur le sujet "Anti-CD20 monoclonal antibodie"

&NA;. « Anti-CD20 monoclonal antibody/thalidomide ». Reactions Weekly &NA;, n^o 855 (juin 2001) : 7. http://dx.doi.org/10.2165/00128415-200108550-00016.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Beers, Stephen A., Ruth R. French, H. T. Claude Chan, Sean H. Lim, Timothy C. Jarrett, Regina Mora Vidal, Sahan S. Wijayaweera et al. « Antigenic modulation limits the efficacy of anti-CD20 antibodies : implications for antibody selection ». Blood 115, n^o 25 (24 juin 2010) : 5191–201. http://dx.doi.org/10.1182/blood-2010-01-263533.

Texte intégral

Résumé :

Abstract Rituximab, a monoclonal antibody that targets CD20 on B cells, is now central to the treatment of a variety of malignant and autoimmune disorders. Despite this success, a substantial proportion of B-cell lymphomas are unresponsive or develop resistance, hence more potent anti-CD20 monoclonal antibodies (mAbs) are continuously being sought. Here we demonstrate that type II (tositumomab-like) anti-CD20 mAbs are 5 times more potent than type I (rituximab-like) reagents in depleting human CD20 Tg B cells, despite both operating exclusively via activatory Fcγ receptor–expressing macrophages. Much of this disparity in performance is attributable to type I mAb-mediated internalization of CD20 by B cells, leading to reduced macrophage recruitment and the degradation of CD20/mAb complexes, shortening mAb half-life. Importantly, human B cells from healthy donors and most cases of chronic lymphatic leukemia and mantle cell lymphoma, showed rapid CD20 internalization that paralleled that seen in the Tg mouse B cells, whereas most follicular lymphoma and diffuse large B-cell lymphoma cells were far more resistant to CD20 loss. We postulate that differences in CD20 modulation may play a central role in determining the relative efficacy of rituximab in treating these diseases and strengthen the case for focusing on type II anti-CD20 mAb in the clinic.

Styles APA, Harvard, Vancouver, ISO, etc.

van Oers, Marinus H. J. « CD20 antibodies : type II to tango ? » Blood 119, n^o 22 (31 mai 2012) : 5061–63. http://dx.doi.org/10.1182/blood-2012-04-420711.

Texte intégral

Résumé :

Although the chimeric anti-CD20 monoclonal antibody (mAb) rituximab has revolutionized the treatment of B-cell non-Hodgkin lymphoma (NHL), still many patients relapse and an increasing number become refractory to rituximab-containing therapy. This has initiated intense research to develop more potent anti-CD20 antibodies.

Styles APA, Harvard, Vancouver, ISO, etc.

Uchida, Junji, Yasuhito Hamaguchi, Julie A. Oliver, Jeffrey V. Ravetch, Jonathan C. Poe, Karen M. Haas et Thomas F. Tedder. « The Innate Mononuclear Phagocyte Network Depletes B Lymphocytes through Fc Receptor–dependent Mechanisms during Anti-CD20 Antibody Immunotherapy ». Journal of Experimental Medicine 199, n^o 12 (21 juin 2004) : 1659–69. http://dx.doi.org/10.1084/jem.20040119.

Texte intégral

Résumé :

Anti-CD20 antibody immunotherapy effectively treats non-Hodgkin's lymphoma and autoimmune disease. However, the cellular and molecular pathways for B cell depletion remain undefined because human mechanistic studies are limited. Proposed mechanisms include antibody-, effector cell–, and complement-dependent cytotoxicity, the disruption of CD20 signaling pathways, and the induction of apoptosis. To identify the mechanisms for B cell depletion in vivo, a new mouse model for anti-CD20 immunotherapy was developed using a panel of twelve mouse anti–mouse CD20 monoclonal antibodies representing all four immunoglobulin G isotypes. Anti-CD20 antibodies rapidly depleted the vast majority of circulating and tissue B cells in an isotype-restricted manner that was completely dependent on effector cell Fc receptor expression. B cell depletion used both FcγRI- and FcγRIII-dependent pathways, whereas B cells were not eliminated in FcR common γ chain–deficient mice. Monocytes were the dominant effector cells for B cell depletion, with no demonstrable role for T or natural killer cells. Although most anti-CD20 antibodies activated complement in vitro, B cell depletion was completely effective in mice with genetic deficiencies in C3, C4, or C1q complement components. That the innate monocyte network depletes B cells through FcγR-dependent pathways during anti-CD20 immunotherapy has important clinical implications for anti-CD20 and other antibody-based therapies.

Styles APA, Harvard, Vancouver, ISO, etc.

Pejcic, Ivica, et Svetislav Vrbic. « Application of anti-CD20 monoclonal antibodies in the treatment of lymphoproliferative diseases ». Archive of Oncology 17, n^o 3-4 (2009) : 65–67. http://dx.doi.org/10.2298/aoo0904065p.

Texte intégral

Résumé :

Out of numerous studied monoclonal antibodies, only a few reached the stage of clinical application. The CD20 molecule, non-glycolysed phospholipoprotein (usually termed B1), belonging to the tetraspan (TM4SF) family, 35-37 kD, is characteristic for all mature B lymphocytes, including CLL cells. The CD20 receptors, characteristic for 'B' lymphoproliferative diseases, have been demonstrated to be a good target for therapeutic effects to be achieved. Rituximab is a chimeric anti-CD20 IgG1 monoclonal antibody, with the sequences of the human constant region and sequences of the murine variable region. It is specifically bound to the B-lymphocyte CD20 antigen. The mechanism of all rituximab antitumor activity has not been established, but ADCC and CDC are believed to be the principal, with possible complementary effects. Therapeutic use of anti-CD20 monoclonal antibodies has demonstrated a significant benefit in the patients with 'B' CD20 positive lymphoproliferative diseases. Rituximab is today a golden standard for the comparation with other treatment modalities, increasingly in combination with chemotherapy.

Styles APA, Harvard, Vancouver, ISO, etc.

Casan, J. M. L., J. Wong, M. J. Northcott et S. Opat. « Anti-CD20 monoclonal antibodies : reviewing a revolution ». Human Vaccines & ; Immunotherapeutics 14, n^o 12 (6 septembre 2018) : 2820–41. http://dx.doi.org/10.1080/21645515.2018.1508624.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Moreno Torres, Irene, et Antonio García-Merino. « Anti-CD20 monoclonal antibodies in multiple sclerosis ». Expert Review of Neurotherapeutics 17, n^o 4 (21 octobre 2016) : 359–71. http://dx.doi.org/10.1080/14737175.2017.1245616.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Taylor, Ronald P., et Margaret A. Lindorfer. « Immunotherapeutic mechanisms of anti-CD20 monoclonal antibodies ». Current Opinion in Immunology 20, n^o 4 (août 2008) : 444–49. http://dx.doi.org/10.1016/j.coi.2008.05.011.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Avivi, Irit, Dina Stroopinsky et Tamar Katz. « Anti-CD20 monoclonal antibodies : Beyond B-cells ». Blood Reviews 27, n^o 5 (septembre 2013) : 217–23. http://dx.doi.org/10.1016/j.blre.2013.07.002.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Habermann, Thomas M. « Antibody Therapy in Aggressive Lymphomas ». Hematology 2007, n^o 1 (1 janvier 2007) : 257–64. http://dx.doi.org/10.1182/asheducation-2007.1.257.

Texte intégral

Résumé :

AbstractThe aggressive lymphomas are potentially curable. The natural history of certain aggressive lymphomas has been altered by monoclonal antibody therapy. Targeted monoclonal antibody therapy to the CD20 antigen has altered the outcome of patients with diffuse large B-cell lymphoma in patients of all ages. Anti-CD20–based radioimmunoconjugates are being evaluated as radioimmunotherapy approaches in patients who have relapsed and in stem cell transplant settings. Antibody-directed therapy to the B-cell–specific antigen CD22 are ongoing. New approaches include different CD20 antibodies and an antibody to the CD40 antigen, which is a member of the tumor necrosis factor (TNF) receptor family, which is expressed on B-cells. Antibody therapy has been incorporated into CHOP (cyclophosphamide, adriamycin, vincristine, prednisone) therapy and other regimens such as EPOCH (etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin) and HyperCVAD (cyclophosphamide, vincristine, adriamycin, dexamethasone). Single-agent anti-CD20 therapy is active in the post-transplantation lymphoproliferative disorders. T-cell antibodies are under evaluation in a number of T-cell lymphoproliferative disorders. Targeted therapy has changed the natural history of a number of aggressive non-Hodgkin lymphomas. This review will describe the contributions of antibody therapies to the treatment of these diseases.

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Thèses sur le sujet "Anti-CD20 monoclonal antibodie"

PIEVANI, ALICE SILVIA. « Cytokine-induced killer (cik) cell cultures for the adoptive immunotherapy of hematological malignancies : characterization and new therapeutic strategies for clinical application ». Doctoral thesis, Università degli Studi di Milano-Bicocca, 2011. http://hdl.handle.net/10281/20178.

Texte intégral

Résumé :

Cytokine-induced killer (CIK) cells are a heterogeneous population of lymphocytes obtained in vitro within 21 days from mononuclear cells under the influence of cytokines. CIK cells show potent MHC-unrestricted cytotoxicity against a variety of tumor cells, in particular hematological malignancies, and minimal tendency to induce graft-versus-host disease. The expanded bulk CIK culture consists of over 90% CD3+ cells, of which the majority coexpress CD56 and the remaining cells are CD56-. CD3+CD56+ “true” CIK cells are terminally differentiated non dividing lymphocytes which could deliver potent MHC-unrestricted cytotoxicity for the immediate destruction of tumor cells. The other less cytotoxic CD3+CD56- cell subset represents a progenitor reservoir that could proliferate and differentiate into CD3+CD56+ CIK cells. CD3+CD56+ CIK cells express activating NK receptors including NKG2D, DNAM-1 and low levels of NKp30. Cell signalling not only through TCR/CD3, but also through NKG2D, DNAM-1 and NKp30, leads to CIK cell activation resulting in granule exocytosis and cytotoxicity. Antibody blocking experiments revealed that NKG2D, DNAM-1 and NKp30 are actually involved in tumor cell recognition and killing. Anti-CMV specific CIK cells could be expanded in standard CIK conditions and mediate both specific, MHC-restricted recognition of a CMV-pulsed autologous target and NK-like non specific cytolytic activity against leukemic cell targets. Antibody blocking of NKG2D and NKp30 only inhibited NK-like cytotoxicity. Their dual effector function suggests that CIK cells, when used in a clinical setting, may control both neoplastic relapses and viral infections, two frequently associated complications in transplanted patients. B-cell non-Hodgkin lymphoma is only partially susceptible to CIK-mediated lysis. The addition of anti-CD20 monoclonal antibodies GA101 or rituximab increased cytotoxicity mediated by CIK cell cultures by 35% and 15%, respectively. This enhancement was mainly due to antibody-dependent cytotoxicity mediated by the 1%-10% NK cells contaminating CIK cultures. The addition of human serum inhibited NK-cell activation induced by rituximab, but not activation induced by GA101. Overall lysis in presence of serum, even of a resistant B-NHL cell line, was significantly increased by 100 mcg/mL of rituximab, but even more so by GA101, with respect to CIK cultures alone. The combined use of CIK cells with anti-CD20 mAbs could represent a novel immunotherapy protocol for the treatment of B lymphoma patients with resistant disease.

Styles APA, Harvard, Vancouver, ISO, etc.

Walshe, Claire Anne. « Signalling cascades induced by type I and II anti-CD20 monoclonal antibodies ». Thesis, University of Southampton, 2006. http://ethos.bl.uk/OrderDetails.do?uin=uk.bl.ethos.436973.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Akanji, Akinkunmi Ganiyu. « "Estudo de marcação com Iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma não-Hodgkin" ». Universidade de São Paulo, 2006. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-31052007-161335/.

Texte intégral

Résumé :

Linfomas são doenças originárias do sistema linfático, descritos por Thomas Hodgkin em 1932. São tradicionalmente classificados em dois grupos básicos: doenças de Hodgkin e linfomas do tipo não hodgkin (LNH). Inicialmente, pacientes com LNH foram tratados com radioterapia apenas ou combinada com imunoterapia usando-se anticorpo monoclonal anti-CD20 (ex., Rituximab-Mabthera, Roche). Porém, radioimunoterapia é uma nova modalidade de tratamento para pacientes portadores de LNH, na qual radiação citotóxica proveniente de radioisótopos terapêuticos é depositada nos tumores via anticorpos monoclonais (Acms). Este estudo concentrou-se nas condições de marcação do Acm anti-CD20 (Rituximab-Mabthera, Roche), com radioiodo (131I), pelo método direto, usando-se Cloramina-T como agente oxidante. Foram estudados parâmetros de marcação tais como: método de purificação, influência de tempo de incubação, influência de massa de agente oxidante, estabilidade in vitro e in vivo, imunoreatividade do anticorpo e distribuição biológica do anticorpo marcado em camundongos Swiss sadios. Produto de alta pureza radioquímica foi obtido, sem diferença notável entre os métodos aplicados. Não foi observada nenhuma influência direta do tempo de incubação na pureza radioquímica do anticorpo marcado. Um pequeno decréscimo na pureza radioquímica foi observado quando variou-se a massa do Acm sem variar a atividade do radioiodo. Após purificação, o anticorpo marcado apresentou pureza radioquímica de aproximadamente 100 %. Observou-se um produto de alta pureza radioquímica quando o anticorpo foi marcado na condição padrão. O anticorpo anti-CD20 apresentou variações de pureza radioquímica quando sua estabilidade foi testada em cinco condições estabilizadoras diferentes. Entretanto, a condição em que ácido gentísico foi combinado com congelamento demonstrou-se apropriada e capaz de minimizar os efeitos de autoradiólise do anticorpo marcado com alta atividade terapêutica de iodo-131. O anticorpo marcado apresentou imunoreatividade abaixo da relatada na literatura. A distribuição biológica em camundongos Swiss sadios revelou captação elevada no pulmão, fígado, e intestino delgado. O clareamento sanguíneo do anticorpo marcado foi relativamente rápido. Contudo, dados experimentais revelaram que anticorpos monoclonais anti-CD20 podem ser seguramente marcados com alta atividade de iodo-131 usando o método de Cloramina-T. O uso de cromatografia em camada delgada (ITLC-SG) na avaliação de pureza radioquímica mostrou-se apropriado, eficiente, prático, além de simples e rápido. O método de purificação utilizado demonstrou-se eficiente para a separação do anticorpo marcado do iodo livre. A abordagem inédita apresentada neste estudo, no sentido de viabilizar transporte e comercialização do produto marcado, referiu-se ao estudo de estabilidade do Acm marcado. A distribuição biológica do anticorpo demonstrou-se compatível com a distribuição do anticorpo íntegro indicando ótima estabilidade relativa in vivo. Os resultados deste estudo confirmam a potencialidade do anticorpo para a radioimunoterapia de linfomas do tipo não-Hodgkin.
Lymphomas are malignancies of the lymphatic system, described by Thomas Hodgkin in 1932. Traditionally, lymphomas are classified in two basic groups: Hodgkin disease and non-Hodgkin lymphoma (NHL). Patients with NHL were earlier treated with radiotherapy alone or in combination with immunotherapy using monoclonal antibody anti-CD20 (ex., Rituximab-Mabthera, Roche). However, Radioimmunotherapy is a new modality of treatment for patients with NHL, in which cytotoxic radiation from therapeutic radioisotopes is delivered to tumors through monoclonal antibodies. This study focused on labeling conditions of monoclonal antibody anti-CD20 (Rituximab-Mabthera, Roche) with iodine-131, by direct radioiodination method using Chloramine-T as oxidizing agent. Labeling parameters investigated were: Radiochemical purity (RP), method of purification, incubation time, antibody mass, oxidative agent mass, stability in vitro, stability in vivo, immunoreactivity and biological distribution performed in normal Swiss mouse. Product of high radiochemical purity was obtained with no notable difference between the methods applied. No clear evidence of direct influence of incubation time on radiochemical purity of the labeled antibody was observed. Whereas, a clear evidence of direct influence of activity on radiochemical purity of the labeled antibody was observed when antibody mass was varied. After purification, the labeled product presented radiochemical purity of approximately 100 %. Product of superior radiochemical yield was observed when standard condition of labeling was used. The labeled product presented variation in radiochemical purity using five different stabilizer conditions. The condition in which gentisic acid was combined with freeze appears more suitable and capable of minimizing autoradiolysis of the antibody labeled with high therapeutic activity of iodine-131. The labeled product presented low immunoreactivity when compared to the literature. Biological distribution in normal Swiss mouse demonstrated high uptake of the labeled antibody in lungs, liver, and small intestine. The progressive loss of activity in blood indicates fast blood clearance of the labeled antibody that is eliminated through the kidney, in urine. The experimental data proved that mAb anti-CD20 can be securely labeled with high therapeutic activity of iodine-131 using Chloramine-T method. Radiochemical purity determined by chromatographic plates (ITLC-SG) proved to be appropriate, efficient, practical and simple. The purification method demonstrated to be appropriate and efficient for separating the labeled antibody from free iodine. The results of stability of the labeled antibody presented in this study suggest that the product can be transported and commercialized using the condition in which gentisic acid was combined with freeze. In vivo distribution of the labeled antibody shows to be compatible with integral antibody distribution, indicating good in vivo stability. Results obtained in this study confirmed the potential of the labeled product anti-CD20-131I for radioimmunotherapy of non-Hodgkin lymphoma (NHL).

Styles APA, Harvard, Vancouver, ISO, etc.

DIAS, CARLA R. de B. R. « Estudo comparativo da marcacao do anticorpo anti-CD20 com sup(188)Re ». reponame:Repositório Institucional do IPEN, 2010. http://repositorio.ipen.br:8080/xmlui/handle/123456789/9502.

Texte intégral

Résumé :

Made available in DSpace on 2014-10-09T12:27:22Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:06:35Z (GMT). No. of bitstreams: 0
Tese (Doutoramento)
IPEN/T
Instituto de Pesquisas Energeticas e Nucleares - IPEN-CNEN/SP

Styles APA, Harvard, Vancouver, ISO, etc.

Spasevska, Ivana. « The role of EGR-1 and calcium influx in the antitumor activity of anti-CD20 monoclonal antibodies ». Thesis, Lyon, 2017. http://www.theses.fr/2017LYSE1304/document.

Texte intégral

Résumé :

Les anticorps monoclonaux (AcM) anti-CD20 sont essentiels pour le traitement du lymphome non hodgkinien et de la leucémie lymphoïde chronique (LLC). Les AcM agissent soit en activant directement la signalisation apoptotique dans les cellules cibles, soit via le système immunitaire. Dans une étude préclinique, nous avons montré que le traitement avec AcM anti-CD20, rituximab et GA101, induit l'expression de la protéine early growth response 1 (EGR-1) (Dalle et al., 2011). EGR-1 est un facteur de transcription régulé par le calcium (Ca2+) et CD20 est impliqué dans la régulation du flux calcique transmembranaire. Nous avons donc étudié le rôle d'EGR-1 et du flux Ca2+ dans l'activité cytotoxique des AcM anti-CD20. Nous avons montré qu'EGR-1 est rapidement induit suite à l'exposition au rituximab et à GA101. La baisse de l'expression d'EGR-1 par shRNA a supprimé l'effet cytotoxique du GA101 à la fois in vitro et in vivo, indiquant qu'EGR-1 est requis pour la mort cellulaire médiée par CD20. De plus, la surexpression d'EGR-1 augmente la sensibilité au GA101 in vitro et in vivo. En outre, nos résultats indiquent que les AcM anti-CD20 induisent un flux Ca2+. Le blocage du flux Ca2+ par inhibiteurs de canaux calciques (ICC) a aboli l'induction d'EGR-1 ainsi que l'efficacité du GA101 in vivo et ex vivo dans des échantillons de LLC. Plus important, nos données indiquent que les patients recevant des ICC ont une moins bonne réponse au traitement par les AcM anti-CD20. En conclusion, nous avons identifié EGR-1 comme potentiel biomarqueur pour prédire la réponse à la thérapie anti-CD20 et démontré que les ICC ont un impact négatif sur l'efficacité des AcM anti-CD20 chez les patients
Anti-CD20 monoclonal antibodies (mAbs) are an essential component of the treatment of patients with non-Hodgkin's lymphoma and chronic lymphocytic leukemia (CLL). They mediate their antitumor effects by activating the immune system or by direct apoptotic signaling in target cells. In a previous preclinical study, we showed that treatment with anti-CD20 mAbs, rituximab and GA101, resulted in upregulated expression of early growth factor 1 (EGR-1) (Dalle et al. 2011). EGR-1 is a calcium (Ca2+) regulated transcription factor and CD20 is hypothesized to regulate transmembrane Ca2+ flux. Therefore, we aimed to assess the role of EGR-1 and Ca2+ flux in the cytotoxic activity of anti-CD20 mAbs. We have shown that EGR-1 expression is rapidly upregulated in CD20+ cells following rituximab and GA101 exposure. Decreasing EGR-1 expression by shRNA abolishes the direct cytotoxic effect of GA101 both in vitro and in vivo, indicating that EGR-1 is required for CD20-mediated cell death. Additionally, the overexpression of EGR-1 enhances the cytotoxic activity of GA101 both in vitro and in vivo. Furthermore, our results indicate that anti-CD20 mAbs induce calcium influx. Blocking the Ca2+ flux with calcium channel blockers (CCB) abolishes EGR-1 induction and impaires the GA101 efficacy in vivo and ex vivo in CLL blood samples. More importantly, our data indicate that patients receiving CCBs and anti-CD20 therapy have worst progression free survival and overall survival. In conclusion we have identified EGR-1 as a potential biomarker to predict response to anti-CD20 therapy. We demonstrated that co-treatement with CCBs negatively impacts the outcome of patients receiving anti-CD20 mAbs

Styles APA, Harvard, Vancouver, ISO, etc.

Tipton, Thomas R. W. « Understanding the role for Fc gamma receptors in response to anti-CD20 monoclonal antibody therapy ». Thesis, University of Southampton, 2015. https://eprints.soton.ac.uk/415837/.

Texte intégral

Résumé :

Research into cancer therapeutics has utilized the antigen specificity of antibodies to provide targeted cancer treatments. One notable therapeutic is rituximab, a chimeric human IgG1 antibody that has specificity to the CD20 protein on the surface of B cells. This antibody is currently used in the treatment of leukaemia and lymphoma. However, due to reasons not fully understood patients often relapse and become resistant to therapy. Therefore an increasingly important area of research is to uncover the key mechanisms of action of anti-CD20 antibodies. It has been demonstrated that antibody Fc: FcγR interactions are critical foreffective anti-CD20 antibody dependent cellular cytotoxicity (ADCC). During this project the role of Fc: FcγR interactions and their ability to mediate anti-CD20 mediated B cell depletion was explored. We assessed two different types of anti-CD20 antibody: type I, rituximab has been shown to have high levels of antibody:antigen internalisation following CD20 engagement. This process has been termed antigenic modulation. In contrast, type II, obinutuzumab do not display a high level of antigenic modulation. We assessed the ability of rituximab and obinutuzumab to deplete normal and malignant B cells. Additionally, macrophages and NK cells have both been implicated as key FcγRexpressing effector cells. Therefore, we assessed rituximab and obinutuzumab using in vitro macrophage or NK cell mediated ADCC assays and looked at the impact antigenic modulation had on effector cell activity. In vivo analysis revealed that obinutuzumab give more sustained B cell depletion compared to rituximab. Furthermore, we demonstrate that this sustained depletion is due to a lack of antigenic modulation preventing NK cell and macrophage mediated ADCC. In contrast rituximab undergoes significant internalisation preventing both NK cell and macrophage mediated ADCC. In addition, it has been well documented that the tumour microenvironment will affect the phenotype of the surrounding stroma, particularly macrophages. Established tumours are typically associated with low levels of apoptosis. Therefore, we investigated the impact dysregulated apoptosis had on the ability of macrophages to orchestrate ADCC. Using apoptosis resistant Vav Bcl-2 mice, as well as other apoptosis defective strains, we demonstrate that there is a decrease in the activatory to inhibitory FcγR ratio on effector cell subsets. This was largely due to an increase in inhibitory FcγRIIb. Subsequent analysisrevealed that an increase in FcγRIIb may be due to the autoimmune-likephenotype of the Vav Bcl-2 mouse. This knowledge will be beneficial to future consideration of antibody selection and provides further avenues of research into antibody and FcγR interactions.

Styles APA, Harvard, Vancouver, ISO, etc.

Middleton, Odette. « Investigation into the efficacy of the anti-CD20 monoclonal antibody ofatumumab in chronic lymphocytic leukaemia ». Thesis, University of Glasgow, 2015. http://theses.gla.ac.uk/7125/.

Texte intégral

Résumé :

Chronic lymphocytic leukaemia (CLL) is the most common leukaemia of the Western world, and unfortunately despite advances in chemotherapeutic agents CLL remains incurable to date. CLL is a highly heterogeneous disease. CLL patients exhibiting progressive disease often become refractory to standard first line therapies, underpinning the need for novel drugs. An emerging field is targeted monoclonal antibody (MAb) development. Rituximab (RTX) a chimeric anti-CD20 MAb is registered as a first line therapy in combination with fludarabine and cyclophosphamide. A next generation type I, human IgG1 anti-CD20 MAb, ofatumumab (OFA), binds to a novel epitope of CD20 resulting in higher potency of complement dependent cytotoxicity (CDC) induction. OFA has recently been given FDA approval for treatment in combination with chlorambucil for previously untreated CLL patients when fludarabine based regimes are not appropriate. OFA is also licensed as a single agent for the treatment of CLL patients refractory to both fludarbine and anti-CD52 MAb alemtuzumab. This research was conducted to establish what factors within CLL biology may influence RTX or OFA efficacy, in order to highlight the improved activity of OFA in comparison to RTX for the treatment of CLL. The ability of OFA to elicit a CDC response is an important part of its efficacy. Within this study we have demonstrated that OFA activity is limited in the treatment of CLL by several different factors including; complement levels, CD20 expression, microenvironmental stimulation and CLL genetic mutations. Our study identified that a large proportion, 37.5%, of CLL patients harbour complement deficiencies within their sera, this then led to a significant amount of complement exhaustion with successive OFA treatments, abrogating CDC induction. The detection of excessive complement exhaustion potentially has a clinical impact on the administration of anti-CD20 MAbs. CD20 expression levels also impact upon CDC induction by OFA, CD20 expression levels display a positive linear correlation with the percentage of CDC induction. Importantly OFA is superior in the induction of CDC in CLL patients with low CD20 expression levels in comparison to RTX. It is well established that CLL patients have lower CD20 expression compared to other B cell malignancies, which is an important factor for anti-CD20 MAb efficacy as CDC induction is critically dependent on the expression levels of the target antigen on the surface of the cell. Recurrent mutations within NOTCH1 (NOTCH1MUT) have recently been identified as a poor prognostic marker within CLL. Emerging data suggests this mutation confers resistance against anti-CD20 MAbs, possibly through a down-regulation of CD20. We demonstrate that NOTCH1MUT CLL cells do display reduced expression levels of CD20, however this alone did not appear to contribute to all the reduced susceptibility towards anti-CD20 MAb activity. Preliminary gene expression data in combination with Ca2+ flux analysis suggest that NOTCH1MUT CLL cells have deregulated Ca2+ signalling which highlights the role of CD20 as a store-operated Ca2+ channel, and provides another mechanism for their resistance. Microenvironmental stimulation also impacts upon CLL cell response to RTX and OFA. Mimicking CLL cell interaction with their microenvironmental niche, caused an increase in CDC induction within different CLL cytogenetic subsets, independently to changes in CD20 expression. This is important as the interaction of CLL cells with other components of the microenvironment cause an up-regulation of anti-apoptotic proteins aiding CLL survival and promoting drug resistance. In conclusion this study highlights the increased efficacy of OFA as a chemotherapeutic agent in the treatment of CLL in comparison to RTX. Collectively these results also demonstrate that a change within the dosing schedule of OFA and complement supplementation using an exogenous source such as fresh frozen plasma could diminish some of the limitations in CDC induction, and potentially lead to enhanced clinical efficacy.

Styles APA, Harvard, Vancouver, ISO, etc.

Reslan, Lina. « Comparison of the cytotoxic mechanisms of anti-CD20 monoclonal antibodies Rituximab and GA101 in Chronic Lymphocytic Leukemia ». Thesis, Lyon 1, 2010. http://www.theses.fr/2010LYO10346/document.

Texte intégral

Résumé :

CD20 est une cible thérapeutique validée pour l’immunothérapie des néoplasmes lymphoïdesdes cellules B, incluant la Leucémie Lymphoïde Chronique (LLC). Nous avons comparé les effets de rituximab et de GA101 (nouvel anticorps anti-CD20) contre les cellules LLC fraiches in vitro. Le marquage avec Annexine V a démontré une induction de l’apoptose après l’exposition au rituximab et GA101.Contrairement au rituximab, GA101 induisait une réduction du potentiel transmembranaire mitochondrial, uneffet qui peut être partiellement inhibé par la cyclosporine A et qui est partiellement caspase-dépendant. GA101induisait aussi la production des espèces d’oxygènes réactives. L’analyse du niveau d’expression des protéinespro- et anti-apoptotiques après exposition aux anticorps a démontré une forte hétérogénéité entre les échantillons.Bax subissait une activation de conformation et une translocation mitochondriale suite à l’exposition aux anticorps d’une manière caspase-indépendante. GA101, mais pas rituximab, induisait le clivage des caspase-8, -9et -3. En transfectant les cellules LLC avec un siRNA ciblant Bcl-xL utilisant la sonoporation, nous avons trouvéque la réduction du niveau d’expression de Bcl-xL est associée à une augmentation de la sensibilité aux anticorps. Nos résultats suggèrent que les voies de signalisation apoptotiques diffèrent entre rituximab et GA101avec une implication de la voie mitochondriale avec le GA101. L’inhibition de Bcl-xL peut constituer une façon pour sensibiliser les cellules LLC aux effets apoptotiques des anticorps anti-CD20
CD20 is a validated target for the immunotherapy of B lymphoid neoplasms, including ChronicLymphocytic Leukemia (CLL). We compared the activities of rituximab and GA101 (novel anti-CD20 antibody)on fresh human CLL cells in vitro. AnnexinV staining demonstrated induction of apoptosis after exposure torituximab or GA101. Unlike rituximab, GA101 induced a reduction of the mitochondrial transmembranepotential, an effect which could be partially inhibited by cyclosporin A and which was partially caspasedependent.GA101 was also found to induce the production of Reactive Oxygen Species. Analysis of pro- andanti-apoptotic protein content after exposure to antibodies demonstrated a strong degree of heterogeneity between samples. Bax underwent conformational activation and mitochondrial translocation upon exposure toantibodies in a caspase-independent manner. GA101 but not rituximab induced cleavage of caspase-8, -9 and -3.By transfecting CLL cells with anti-Bcl-xL siRNA using a sonoporation method, we found that reduction of BclxLcontent was associated with increased sensitivity to these antibodies. Our results suggest that apoptoticsignalization pathways differ between rituximab and GA101 with a greater involvement of the mitochondrialpathway for GA101. Inhibition of Bcl-xL could constitute an approach to sensitize CLL cells to the apoptoticeffects of anti-CD20 antibodies

Styles APA, Harvard, Vancouver, ISO, etc.

AKANJI, AKINKUNMI G. « Estudo de marcação com iodo-131 de anticorpo monoclonal anti-CD20 usado na terapia de linfoma nao-hodgkin ». reponame:Repositório Institucional do IPEN, 2006. http://repositorio.ipen.br:8080/xmlui/handle/123456789/11488.

Texte intégral

Résumé :

Made available in DSpace on 2014-10-09T12:52:27Z (GMT). No. of bitstreams: 0
Made available in DSpace on 2014-10-09T14:01:38Z (GMT). No. of bitstreams: 0
Dissertação (Mestrado)
IPEN/D
Instituto de Pesquisas Energeticas e Nucleares - IPEN/CNEN-SP

Styles APA, Harvard, Vancouver, ISO, etc.

Akanji, Akinkunmi Ganiyu. « Estudo de conjugação do anticorpo anti-CD20 para marcação com radionuclídeos metálicos ou lantanídeos ». Universidade de São Paulo, 2013. http://www.teses.usp.br/teses/disponiveis/85/85131/tde-06092017-084114/.

Texte intégral

Résumé :

Linfomas são cânceres que se iniciam a partir da transformação maligna de um linfócito no sistema linfático. Os linfomas são divididos em duas categorias principais: os linfomas de Hodgkin e todos os outros linfomas, denominados linfomas não-Hodgkin (LNH). Os pacientes com LNH são comumente tratados com radioterapia apenas ou combinada com quimioterapia utilizando-se de anticorpo monoclonal anti-CD20, principalmente o rituximab (MabThera®). O uso de anticorpos monoclonais (Acm) conjugados à quelantes bifuncionais radiomarcados com radionuclídeos metálicos ou lantanídeos é uma realidade de tratamento para portadores de LNH pelo princípio de radioimunoterapia (RIT). Este estudo concentrou-se nas condições de conjugação do anticorpo monoclonal rituximab (MabThera®) com grupamentos quelantes bifuncionais DOTA e DTPA. Na marcação dos Acm conjugados com lutécio-177, foram estudadas as condições de pré-purificação do Acm, condições de conjugação, determinação de número de quelantes acoplados à molécula do anticorpo, purificação do anticorpo conjugado, radiomarcação do anticorpo conjugado, com lutécio-177, purificação do anticorpo marcado, a ligação específica in vitro dos compostos marcados às células Raji, e distribuição biológica em camundongos BALB/c sadios. As três metodologias empregadas na pré-purificação do anticorpo (diálise, cromatografia de exclusão molecular com coluna Sephadex G-50 e ultrafiltração) demonstram-se eficientes e proporcionaram recuperação da amostra superior a 90%. A metodologia de ultrafiltração foi considerada a mais simples e prática, podendo ser aplicada a procedimentos rotineiros de produção de radiofármacos. Além disso, proporcionou a recuperação final de amostra de 97% em microlitros. Nas conjugações do anticorpo com os quelantes DOTA e DTPA em razões molares diferentes do Acm:quelante, observou-se número de grupamentos quelantes acoplados à molécula do Acm proporcional à razão molar estudada. Quando foi avaliada a influência de condições diferentes de conjugação no número de quelantes acoplados à molécula do Acm, não foram observadas diferenças significativas, com resultados de pureza radioquímica (PR) inferior a 80% em todas as condições estudadas. Na comparação de métodos de purificação do Acm conjugado, a abordagem inédita apresentada neste estudo, na qual a cromatografia de exclusão molecular foi combinada com a ultrafiltração resultou em maior eficiência na purificação e preservação da estrutura do anticorpo. Nos estudos de radiomarcação do anticorpo conjugado com DOTA e DTPA, os imunoconjugados de DTPA apresentaram, de forma geral, maior eficiência de marcação com resultados reprodutíveis quando comparados com os imunoconjugados de DOTA, considerando-se as diferentes razões molares utilizadas. As metodologias cromatográficas empregadas no controle de pureza radioquímica do composto radiomarcado proporcionaram a discriminação das diferentes espécies radioquímicas no meio de marcação. A metodologia de purificação do composto conjugado e radiomarcado utilizada proporcionou a obtenção de compostos com alta pureza radioquímica, 97,4±1,3% (DOTA 1:50) e 98,7±0,2% (DTPA 1:50). Nos estudos de ligação específica às células tumorais Raji, o anticorpo conjugado com quelante DTPA nas razões molares de 1:50 e 1:20 apresentaram perfil semelhante de ligação, com aumento da porcentagem de ligação específica proporcional à concentração celular, enquanto que o imunoconjugado na razão molar de 1:10 apresentou alta porcentagem de ligação não específica. Os resultados obtidos nos estudos de biodistribuição in vivo do anticorpo conjugado e radiomarcado nem sempre se mostraram compatíveis com a biodistribuição de anticorpos radiomarcados íntegros. No caso do quelante DOTA, o imunoconjugado obtido a partir da razão molar 1:20, apresentou melhores características de biodistribuição. No caso do quelante DTPA, a razão molar utilizada pareceu refletir diretamente no clareamento sanguíneo do anticorpo e todas as razões molares utilizadas apresentaram instabilidade in vivo.
Lymphomas are malignancies or cancers that start from the malign transformation of a lymphocyte in the lymphatic system. Lymphomas are divided in two major categories: Hodgkin lymphoma and non-Hodgkin lymphoma (NHL). Patient with NHL are generally treated with radiotherapy alone or combined with immunotherapy using monoclonal antibody rituximab (MabThera®). Currently, monoclonal antibodies (Mab) conjugated with bifunctional chelate agents and radiolabeled with metallic or lanthanides radionuclides are a treatment reality for patients with NHL by the principle of radioimmunotherapy (RIT). This study focused on the conditions of conjugation of Acm rituximab (MabThera®) with bifunctional chelating agents DOTA and DTPA and labeling with 177-luthetium. Various parameters were studied: method of Acm purification, conditions of Acm conjugation and the determination of the number of chelate coupled to the Acm, the purification of the conjugated Mab, labeling conditions with lutetium-177, purification of the radiolabeled immunoconjugate, radiochemical purity (RP), in vitro specific binding determination to Raji cells (Human Burkitt) and biological distribution performed in normal BALB/c mouse. The three methodologies employed in pre-purification of Acm (dialysis, size exclusion chromatograph and ultrafiltration) demonstrated to be efficient; they provided sample recovery exceeding 90%. However, the methodology of ultrafiltration resulted in greater sample recovery and in microliters. The number of chelate attached to the Mab molecule was proportional to the molar ratio studied. When the influence of different conditions of conjugation in the number of chelate bounded to the Mab was studied, no notable differences were observed. The RP < 80% was observed in all the methods applied. Purification of the conjugated antibody by different methods showed that the innovative combination of Sephadex and ultrafiltration methods resulted in higher efficiency of purification. The optimized conditions for purification of the conjugated antibody preserved the protein integrity. Radiolabelling studies of DOTA and DTPA immunoconjugated showed that DTPA derivatives presented, in general, radiochemical yield superior than DOTA conjugated Mab, considering the different molar ratios studied. The chromatographic methods employed in the RP determination were efficient to separate the different radiochemical species presented in the reaction medium. The methodology used in the purification of the labeled Mab resulted in labeled compounds with high radiochemical purity, 97.4±1.3% (DOTA 1:50) and 98.7±0.2% (DTPA 1:50). Considering specific cell binding assays (Raji cells), the Mab conjugated to DTPA at 1:50 and 1:20 molar ratios presented similar results, and the percent of cell binding were proportional to the cell concentration, whereas the cell binding for 1:10 molar ratio showed high percent of nonspecific cell binding. The results of in vivo biodistribution studies of labeled Mab not always were compatible with the biodistribution of intact radiolabelled antibody. The DOTA immunoconjugated produced at 1:20 molar ratio, showed better performance in biodistribution studies. In the case of DTPA immunoconjugated, the blood clearance seems to be influenced by the molar ratio applied and the immunoconjugated produced with DTPA chelate at different molar ratio resulted in high in vivo instability compounds.

Styles APA, Harvard, Vancouver, ISO, etc.

Plus de sources

Chapitres de livres sur le sujet "Anti-CD20 monoclonal antibodie"

Pescovitz, Mark D. « Rituximab, an Anti-CD20 Monoclonal Antibody ». Dans Immunotherapy in Transplantation, 362–77. Oxford, UK : Wiley-Blackwell, 2012. http://dx.doi.org/10.1002/9781444355628.ch24.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Godeau, Bertrand. « Monoclonal Anti-CD20 (B-Cell) Antibody and Autoimmune Diseases ». Dans Antibody Therapy, 343–63. Cham : Springer International Publishing, 2018. http://dx.doi.org/10.1007/978-3-319-68038-5_21.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Looney, R. John, Jennifer Anolik et Inaki Sanz. « Treatment of SLE with Anti-CD20 Monoclonal Antibody ». Dans Current Directions in Autoimmunity, 193–205. Basel : KARGER, 2004. http://dx.doi.org/10.1159/000082104.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Krause, M., Ch von Auer, I. Stier-Brück et I. Scharrer. « Successful Therapy with anti CD20 Monoclonal Antibody Rituximab in Patients with Acquired Hemophilia against Factor VIII ». Dans 35th Hemophilia Symposium, 187–89. Berlin, Heidelberg : Springer Berlin Heidelberg, 2006. http://dx.doi.org/10.1007/3-540-28546-6_37.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Woodhouse, Andrew. « Case 38 ». Dans Oxford Case Histories in Infectious Diseases and Microbiology, sous la direction de Andrew Woodhouse, 261–66. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198846482.003.0038.

Texte intégral

Résumé :

Post-transplant lymphoproliferative disease (PTLD) is a disorder of lymphoid proliferation seen in recipients of solid organ or haematopoietic transplants as a consequence of immunosuppression. A spectrum of disease is recognized ranging from non-malignant polyclonal proliferation of B cells to monoclonal proliferation of B or T lymphocytes which have features in common with lymphomas. Epstein–Barr virus (EBV) is associated with a majority of cases although it is not a universal feature. Treatment with anti-CD20 antibody in addition to reduction in immunosuppression has become the most common treatment approach.

Styles APA, Harvard, Vancouver, ISO, etc.

Clara, Joseph A., et Naoko Takebe. « Anti-CD20 Monoclonal Antibody Treatment in Follicular Lymphoma and Chronic Lymphocytic Leukemia ». Dans Handbook of Therapeutic Biomarkers in Cancer, 633–61. Jenny Stanford Publishing, 2020. http://dx.doi.org/10.1201/9781003159469-18.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Winkler, U., V. Diehl et A. Engert. « Clinical Investigation of the Monoclonal Anti-CD20 Antibody Rituximab (IDEC-C2B8) in Patients with B Cell Lymphoma ». Dans Contributions to Oncology, 343–60. S. Karger AG, 1999. http://dx.doi.org/10.1159/000425847.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Zivelonghi, Cecilia, et Andrew McKeon. « A Girl With Back Pain, Paresthesias, and Painful Vision Loss ». Dans Mayo Clinic Cases in Neuroimmunology, sous la direction de Andrew McKeon, B. Mark Keegan et W. Oliver Tobin, 44–47. Oxford University Press, 2021. http://dx.doi.org/10.1093/med/9780197583425.003.0014.

Texte intégral

Résumé :

A 12-year-old girl sought care for subacute onset of cramping back pain, along with paresthesias in her lower limbs up to the waistline, both hands, upper back, and chest, followed by rapidly progressive (over a few hours) painful vision loss affecting initially the right eye with subsequent involvement of the left eye. She underwent neuroophthalmologic evaluation and was diagnosed with bilateral optic neuritis. A positive Lhermitte sign was also present. The patient was tested for aquaporin-4-immunoglobulin G autoantibodies, which were positive in both serum and cerebrospinal fluid. A diagnosis of aquaporin-4-immunoglobulin G–positive neuromyelitis optica was made. The patient was treated with rituximab (anti-CD20 monoclonal antibody) and became episode-free, with no further accumulation of disability. The discovery of aquaporin-4-immunoglobulin G in 2004 has permitted the distinction of neuromyelitis optica spectrum disorder from other inflammatory central nervous system disorders. Aquaporin-4-immunoglobulin G represents a highly specific biomarker for neuromyelitis optica (almost 100% using molecular-based techniques), with sensitivity of approximately 80%. According to the most recent diagnostic criteria published in 2015, a diagnosis of neuromyelitis optica spectrum disorder can also be made for patients who are aquaporin-4-immunoglobulin G seronegative by any testing method, regardless of assay sensitivity, provided that more stringent clinical and radiologic requirements are met. Serial testing is recommended for these patients because late seroconversion has been described up to 4 years after the first episode.

Styles APA, Harvard, Vancouver, ISO, etc.

Bhatt, Vijaya Raj, et James O. Armitage. « Non-Hodgkin lymphoma ». Dans Oxford Textbook of Medicine, sous la direction de Chris Hatton et Deborah Hay, 5288–302. Oxford University Press, 2020. http://dx.doi.org/10.1093/med/9780198746690.003.0525.

Texte intégral

Résumé :

Non-Hodgkin’s lymphomas comprise precursor lymphoid neoplasms, mature B-cell neoplasms, and mature T-cell neoplasms. The aetiology of most cases is unknown, but increased risk is associated with immune deficiencies, agricultural chemicals, autoimmune disorders, treated Hodgkin’s disease, and some infectious agents. Incidence varies from 10 to 22 cases per 100 000 per year in different populations. Patients with non-Hodgkin’s lymphoma most commonly present with lymphadenopathy, but other presentations include systemic symptoms or those attributable to mediastinal or retroperitoneal masses or involvement. Diagnosis is typically based on expert evaluation of an adequate lymph node biopsy. Staging depends largely on determining the anatomical extent of disease, with FDG positron emission tomography/CT scanning generally the preferable imaging modality. For most patients, the goal of therapy is to achieve a complete remission. Patients with definitely curable lymphomas, such as diffuse large B-cell lymphoma and Burkitt’s lymphoma, are almost always treated promptly with intensive regimens, for example, chemotherapy with CHOP (cyclophosphamide, doxorubicin, vincristine (Oncovin), and prednisone) plus the anti-CD20 monoclonal antibody rituximab. By contrast, follicular lymphoma is often not curable and the best treatment is not clear, with many physicians favouring no initial therapy in an asymptomatic patient. Patients who are not cured with initial therapy are candidates for what has been termed ‘salvage therapy’. For most patients, the only curative approach in this setting is haematopoietic stem cell transplantation, the toxicity of which means that it is only sensibly offered to carefully selected patients. Various new agents, such as small molecule kinase and BCL-2 inhibitors, and immune checkpoint inhibitors, offer hope for the future.

Styles APA, Harvard, Vancouver, ISO, etc.

Actes de conférences sur le sujet "Anti-CD20 monoclonal antibodie"

Moskalets, O. V. « Anti-rituximab antibodies in refractory / relapsing cases of chronic lymphocytic leukemia ». Dans General question of world science. L-Journal, 2020. http://dx.doi.org/10.18411/gq-30-11-2020-02.

Texte intégral

Résumé :

Rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, is widley used for treatment of lymphomas, rheumatologic diseases and other – 8 – General question of world science disorders. It is known that many monoclonal antibodies such as rituximab can elicit anti-drug antibodies, which may interfere with therapeutic response. The aim of this study was to investigate the incidence of antibodies to rituximab in patients with chronic lymphocytic leukemia. Serum concentrations of anti-rituximab antibodies was determined in blood serum of patients with B-chronic lymphocytic leukemia (newly diagnosed and resistant / recurrent forms, previously treated by rituximab) and healthy controls. Results: none of the patients with newly diagnosed disease have antibodies to rituximab. Positive results were recorded in 8 (33%) patients who received rituximab earlier

Styles APA, Harvard, Vancouver, ISO, etc.

Moskalets, O. V. « The incidence of anti-rituximab antibodies in patients with chronic lymphocytic leukemia ». Dans Global science. Development and novelty. L-Journal, 2020. http://dx.doi.org/10.18411/gsdn-25-12-2020-05.

Texte intégral

Résumé :

The aim of this study was to investigate the incidence of antibodies to rituximab, a chimeric monoclonal antibody targeted against the pan-B-cell marker CD20, in patients with chronic lymphocytic leukemia. Serum concentrations of anti-rituximab antibodies were determined in patients with B-chronic lymphocytic leukemia (newly diagnosed and resistant / recurrent forms, previously treated by rituximab) and healthy controls. Results: none of the patients with newly diagnosed disease have antibodies to rituximab. Positive results were recorded in 8 (33%) patients who received rituximab earlier.

Styles APA, Harvard, Vancouver, ISO, etc.

Damasceno Júnior, Eustáquio Costa, Isabella Sabião Borges, João Victor Aguiar Moreira, Pedro Otávio Rego de Aguiar, Thaciany Soares Ferreira, Leonardo Peixoto Garcia, Glauber Mota Pacheco et al. « Successful treatment with rituximab in a refractory Stiffperson syndrome (SPS) ». Dans XIII Congresso Paulista de Neurologia. Zeppelini Editorial e Comunicação, 2021. http://dx.doi.org/10.5327/1516-3180.507.

Texte intégral

Résumé :

Background: SPS is a disorder consisting of rigidity of axial muscles with painful spasms. More than 80 % of SPS patients have high titer antibodies against glutamic acid decarboxylase (GAD). The use of rituximab for the treatment of SPS is a recent therapeutical approach showing promising results. We present a case of SPS treated with rituximab, showing a good and safe response. Case: A 38-year-old female patient presented with a history of rigidity of abdominal and paravertebral muscles associated with painful spasms in lower back region, increased tonus, lumbar lordosis, frequent falls and severe functional limitation. The anti-GAD antibodies were positive in high titles. Electromyography showed continuous motor activity with normal morphology especially on paravertebral muscles. She had a partial response to baclofen and diazepam, but could not tolerate it because of somnolence, and started the treatment with rituximab. After one year, the baclofen was discontinued and the diazepam reduced. The axial stiffness and spasm frequency improved, including postural instability, without new episodes of falls. Discussion: Rituximab is a monoclonal antibody targeting the CD20 antigens on the surface of mature B lymphocytes. After binding to these antigens, it initiates a cascade of biochemical events leading to apoptosis. Its use has been approved for numerous diseases with promising results. The use of rituximab in the treatment of SPS is a recent approach and good results have been reported. Conclusion: Rituximab may be a promising option in SPS treatment. However, this is a preliminary paper showing partial results requiring long-term follow-up.

Styles APA, Harvard, Vancouver, ISO, etc.

Zerrouqi, Abdessamad, Nina Miazek-Zapala, Anna Torun, Piotr Zapala, Jakub Golab, Magdalena Winiarska et Beata Pyrzynska. « Abstract LB-261 : Salinomycin expands the cytotoxicity of both anti-CD20 monoclonal antibodies and natural killer cells towards non-Hodgkin lymphomas ». Dans Proceedings : AACR Annual Meeting 2019 ; March 29-April 3, 2019 ; Atlanta, GA. American Association for Cancer Research, 2019. http://dx.doi.org/10.1158/1538-7445.sabcs18-lb-261.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Wayne, Jennifer L., Mary-Ann Campbell, Shashi Marulappa et Vinay Jain. « Abstract 3784 : AME-133v, a humanized, Fc-engineered anti-CD20 monoclonal antibody, demonstrates greater B cell depletion than Rituxanin vitro ». Dans Proceedings : AACR 103rd Annual Meeting 2012‐‐ Mar 31‐Apr 4, 2012 ; Chicago, IL. American Association for Cancer Research, 2012. http://dx.doi.org/10.1158/1538-7445.am2012-3784.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Montraveta, Arnau, Merce de Frias, Clara Campas, Elias Campo, Gael Roue et Dolors Colomer. « Abstract A209 : The nucleoside analogue acadesine exerts antitumoral activity and cooperates with anti-CD20 monoclonal antibodies in in vitro and in vivo models of mantle cell lymphoma. » Dans Abstracts : AACR-NCI-EORTC International Conference : Molecular Targets and Cancer Therapeutics--Nov 12-16, 2011 ; San Francisco, CA. American Association for Cancer Research, 2011. http://dx.doi.org/10.1158/1535-7163.targ-11-a209.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Hilton, Laura K., Malgorzata Nowicka, Margaret Ashton-Key, Chantal E. Hargreaves, Chern Lee, Russell Foxall, Matthew J. Carter et al. « Abstract PO-26 : Prognostic significance of Fc gamma receptor IIB expression in the response of previously untreated diffuse large B-cell lymphomas to anti-CD20 monoclonal antibodies : Differing impact of rituximab and obinutuzumab ». Dans Abstracts : AACR Virtual Meeting : Advances in Malignant Lymphoma ; August 17-19, 2020. American Association for Cancer Research, 2020. http://dx.doi.org/10.1158/2643-3249.lymphoma20-po-26.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Fehniger, Todd A., Brian T. Hess, Veronika Bachanova, Michelle Becker-Hapak, Ethan McClain, Melissa Berrien-Elliott, Julia Wagner et al. « Abstract CT146 : First-in-human phase I combination of the IL-15 receptor super agonist complex ALT-803 with a therapeutic (anti-CD20) monoclonal antibody (mAb) for patients with relapsed or refractory indolent non-Hodgkin lymphoma (iNHL) ». Dans Proceedings : AACR Annual Meeting 2018 ; April 14-18, 2018 ; Chicago, IL. American Association for Cancer Research, 2018. http://dx.doi.org/10.1158/1538-7445.am2018-ct146.

Texte intégral

Styles APA, Harvard, Vancouver, ISO, etc.

Nous offrons des réductions sur tous les plans premium pour les auteurs dont les œuvres sont incluses dans des sélections littéraires thématiques. Contactez-nous pour obtenir un code promo unique!